In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by Russ Lebovitz, M.D., Ph.D., CEO and co-founder of Amprion. They discuss their strategic collaboration and the innovative SAAmplify™–αSYN (CSF) test. They covered:

• Details about how the cerebrospinal fluid biomarker test (Mayo ID: ASYNC) benefits patients exhibiting signs and symptoms of clinically uncertain cognitive decline or clinically uncertain Parkinsonian syndromes.
• Groundbreaking science on proteins that Amprion leveraged to create a solution that meaningfully impacts patient care and provides value to clinicians.
• Information physicians receive from the test, and when they should consider ordering it for their patients.
• Opportunities to change diagnostic journeys by providing accurate, early diagnosis with SAAmplify–αSYN.

Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' SPAS test identifies the form of arsenic present in patients with arsenic exposure. That information is important for determining the potential level of harm and for removing the patient from the arsenic source to ease symptoms and prevent cancer risk.

Speaker 3: (00:33)
Do you mind telling us a little bit about yourself and your background?

Speaker 3: (01:45)
Could you please provide us with an overview of arsenic, how people get exposed, and the laboratory testing for arsenic and arsenic speciation?

Speaker 3: (05:25)
Which patients should have this testing, and when should it be performed?

Speaker 3: (06:57)
What alternative test options are available, and how does testing at Mayo Clinic compare?

Speaker 3: (08:37)

How are the results used in patient care?

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the recent court judgment on the U.S. Food and Drug Administration’s (FDA) oversight of lab-developed tests (LDT). They covered:

• Details about the ruling to vacate the FDA’s rule on LDT oversight.
• What LDT oversight might look like in the future.
• How the laboratory medicine industry can help create an oversight approach that is positive for both patients and innovation.